# Prolexys Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/prolexys-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Salt Lake City, US
- Website: www.prolexys.com
- Total disclosed funding: $20M
- Latest round: Series A (Nov 5, 2008)
- Investors on record: 1

## About

Prolexys Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative therapeutic solutions to address unmet medical needs in various disease areas, leveraging cutting-edge research and technology.Prolexys Pharmaceuticals Inc. was founded in 2001 and is headquartered in Salt Lake City, US. The company specializes in biopharmaceutical innovations. In November 2008, the firm raised USD 20 mn in a Series A funding round led by New Venturetec. The total amount raised to date is USD 20 mn, with only one recorded deal.Prolexys Pharmaceuticals offers a range of innovative biopharmaceutical products designed to address specific medical needs. Their core focus includes developing advanced therapeutic solutions aimed at various disease areas, which are tailored to meet the demands of healthcare providers. Additionally, the company engages in extensive research and development activities to ensure the efficacy and safety of their products. Their offerings are marketed primarily in North America and Europe, with expansion efforts targeting the Asia-Pacific region as well.The company's revenue generation primarily occurs through the commercialization of its biopharmaceutical products, which are distributed via strategic partnerships with healthcare providers and institutions. Their revenue model is structured to support sustainable long-term client relationships, with a focus on ensuring accessibility and availability of their therapeutic innovations. Each product is designed to meet specific patient needs, contributing to a direct engagement strategy with healthcare professionals.Prolexys Pharmaceuticals is focused on expanding its product line with new therapeutic solutions currently in the development phase, aiming for launch in the next two years. They plan to enter the Asia-Pacific market by 2025, capitalizing on the growing demand for biopharmaceuticals in the region. The recent funding of USD 20 mn raised in November 2008 will be utilized to support these initiatives, facilitating research and development, as well as market entry strategies.

## Funding rounds

- Series A, Nov 5, 2008, $20M — New Venturetec

## Investors

- New Venturetec (https://capitalatlas.ai/funds/new-venturetec) — Series A